Упрощенная HTML-версия
E. Dadachova, L. A. Pirofski // Nat. Rev. Microbiol. - 2004. - Vol. 2, № 9. -
P. 695-703.
328. Casadevall, A. The potential of antibody-mediated immunity in the defence against
biological weapons / A. Casadevall, L. A. Pirofski // Expert Opin. Biol. Ther. -
2005.-Vo l. 5, № 10 .-P . 1359-1372.
329. Cell surface expression of yellow fever virus non-structural glycoprotein NS1:
consequences of interaction with antibody / Schlesinger, J. J., M. W. Brandriss,
J. R. Putnak, and E. E. Walsh // J. Gen. Virol. - 1990. - Vol. 71. - P. 593-599.
330. Chan, D. C. HIV entry and its inhibition // D. C. Chan, P. S. Kim // Cell. -
1998.-V o l . 93 .-P . 681-684.
331. Characterization of chimpanzee/human monoclonal antibodies to vaccinia
virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia
virus mouse protection model / Z. Chen [et al.] // J. Virol. - 2007. - Vol. 81. -
P. 8989-8995.
332. Characterization of a type-common human recombinant monoclonal antibody to
herpes simplex virus with high therapeutic potential / A. De Logu [et al.] // J. Clin.
Microbiol.- 1998. - Vol. 36. - P. 3198-3204.
333. Clinical and immunological risk factor for sever disease in Japanese encephalitis
/ D. H. Libraty [et al.] // Trans. R. Soc. Trop. Med. Hyg. - 2002. - Vol. 96,
№ 2 . -P . 173-178.
334. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV)
monoclonal antibodies in the RSV murine model: time versus potency / A. Mejias
[et al.] // Antimicrob. Agents Chemother. - 2005. - Vol. 49. - P. 4700-4707.
335. Comparative evaluation of the indirect immunoperoxidase test for the serodiagnosis
of rickettsial disease / D. J. Kelly [et al.] // Am. J. Trop. Med. Hyg. - 1988. -
Vol. 38, № 2 . -P . 400-406.
336. Construction of human Fab library and isolation of monoclonal Fabs with rabies
virus-neutralizing ability / T. Ando [et al.] // Microbiol. Immunol. - 2005. -
Vol. 49 .-P . 311-322.
337. Cook, D. J. Systematic reviews: synthesis of best evidence for clinical decisions /
D. J. Cook, C. D. Mulrow, R. B. Haynes // Ann. Intern. Med. - 1997. - Vol. 126,
№ 5 . -P . 376-380.
338. Core SPC for human tick-borne encephalitis immunoglobulin for intramuscular
use (CPMP/BPWG/3732/02 [Electronic resourse] / European Medicines Agency.
Human Medicines Evaluation Unit. London, 27 July 2005. Committee for medical
products for human use (CHMP).). - Access mode:
pdfs/human/bpwg /373202en.pdf.
339. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine
design / E. O. Saphire [et al.] // Science. - 2001. - Vol.293. - P. 1155-1159.
340. Cytomegalovirus infection in kidney transplantation: prophylaxis and management
/ P. L. Bulinski et al.] //Transplant. Proc. - 1996. - Vol. 28. - P. 3310-3311.
341. Cytomegalovirus prophylaxis in solid organ transplant recipients / R. Patel [et al.]
// Transplantation. - 1996. - Vol. 61. - P. 1279-1289.
342. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive
transfer of human neutralizing antibodies / A. Trkola [et al.] // Nat. Med. - 2005.
-Vol. 11.-P . 615-622.
343. Demicheli V. Vaccines for preventing tick-borne encephalitis / V. Demicheli,
221